Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic 2

3052 - Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

Date

11 Sep 2017

Session

NSCLC, metastatic 2

Presenters

Silvia Novello

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

S. Novello1, J. Mazieres2, I. Oh3, J. de Castro4, M.R. Migliorino5, A. Helland6, R. Dziadziuszko7, F. Griesinger8, A. Kotb9, A. Zeiter9, A. Cardona9, B. Balas9, H. Johannsdottir9, A. Das-Gupta9, J. Wolf10

Author affiliations

  • 1 Department Of Oncology, University of Turin, 10124 - Torino/IT
  • 2 Thoracic Oncology Department, Toulouse University Hospital, Toulouse/FR
  • 3 Department Of Internal Medicine, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 519-809 - Hwasun/KR
  • 4 Department Of Medical Oncology, University Hospital, Madrid/ES
  • 5 Oncology, A.O. San Camillo Forlanini, Rome/IT
  • 6 Department Of Cancer Genetics And Department Of Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo/NO
  • 7 Department Of Oncology And Radiotherapy, Medical University of Gdansk, Gdansk/PL
  • 8 Department Of Hematology And Oncology, Pius Hospital, OIdenburg/DE
  • 9 Oncology, F. Hoffmann-La Roche Ltd., Basel/CH
  • 10 Center For Intergrated Oncology, University Hospital Cologne, 50937 - Cologne/DE
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3052

Background

ALK+ NSCLC current standard of care is crizotinib. However, many pts experience progressive disease (PD) within a year, often in the central nervous system (CNS). Alectinib (ALC) has shown systemic and CNS efficacy in phase II trials of previously treated ALK+ NSCLC after crizotinib failure. The phase III ALUR study (NCT02604342) investigated efficacy and safety of ALC vs standard relapse chemotherapy (CT) in ALK+ NSCLC previously treated with platinum-based doublet CT and crizotinib.

Methods

Pts aged ≥18 years with previously treated ALK+ NSCLC were randomised 2:1 to ALC (600mg twice daily) or CT (pemetrexed 500mg/m2 q3w or docetaxel 75mg/m2 q3w) until PD, death or withdrawal. Crossover from CT to ALC was permitted after PD. Primary outcome was progression-free survival (PFS) by investigator (INV) assessment. Secondary outcomes included PFS by Independent Review Committee (IRC), overall response rate (ORR) and CNS ORR (CORR) by IRC, disease control rate (DCR), duration of response (DOR) and safety.

Results

107 pts were randomised (ALC n = 72; CT n = 35); 104 received ≥1 dose of study drug (ALC n = 70; CT n = 34). At data cut-off (26.01.17) median follow-up: 6.5 months ALC, 5.8 months CT. Median treatment duration: 20.1 weeks ALC, 6.0 weeks CT. Median PFS by INV was 9.6 months (95% CI 6.9–12.2) ALC, 1.4 months (95% CI 1.3–1.6) CT (HR 0.15, 95% CI 0.08–0.29; p 

Conclusions

ALC significantly improved systemic and CNS efficacy, including PFS and ORR, vs CT for previously treated ALK+ NSCLC, with a favourable safety profile vs CT.

Clinical trial identification

Legal entity responsible for the study

F. Hoffmann - La Roche Ltd.

Funding

F. Hoffmann - La Roche Ltd.

Disclosure

S. Novello: Speaker Bureau: Eli Lilly, BMS, MSD, Astra Zeneca, Roche. J. Mazieres: Honoraria from Novartis, Roche, Pfizer, BMS, MSD. J. de Castro: Membership on an advisory board: Astra-Zeneca, Boehringer, MSD, Novartis, Pfizer, Roche. M.R. Migliorino: Honoraria and Advisory board: Bristol Mayer Squibb, Boehringer Ingelheim, MSD, Astra Zeneca. R. Dziadziuszko: Travel accommodation: Roche. Honoraria: Novartis, Tesaro, Clovis. Honoraria and speakers bureau: Pfizer, Honoraria and consulting role: Boehringer-Ingelheim, Astra-Zeneca, Ignyta. F. Griesinger: Advisory Board and corporate sponsored research: Roche, Astra Zeneca, Lilly, BMS, MSD, Celgene, Boehringer, Pfizer, Novartis. A. Kotb, A. Cardona, B. Balas, H. Johannsdottir, A. Das-Gupta: Employee of F. Hoffmann-La Roche Ltd. A. Zeiter: Employee of F. Hoffmann-La Roche Ltd. with stock ownership. J. Wolf: Advisory boards and lecture fees: AstraZeneca, BMS, Boehringer-Ingelheim, Clovis, Lilly, MSD, Novartis, Pfizer, Roche. Research support: BMS, MSD, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.